CobaltMaghrebV1, Pmc, Curation, bibRecord, 000271

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Identifieur interne : 000271 ( Pmc/Curation ); précédent : 000270; suivant : 000272

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Auteurs : Charles B. Simone [États-Unis] ; John C. Morris [États-Unis] ; Donn M. Stewart [États-Unis] ; Nicole E. Urquhart [Jamaïque] ; John E. Janik [États-Unis] ; Robert J. Kreitman ; Elena Lita ; Kevin Conlon [États-Unis] ; Gilian Wharfe [Jamaïque] ; Thomas A. Waldmann [États-Unis] ; Aradhana Kaushal

Source :

Blood [ 0006-4971 ] ; 2012.

RBID : PMC:3433088

Abstract

Human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control across ATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433088

DOI: 10.1182/blood-2012-01-401349
PubMed: 22730536
PubMed Central: 3433088

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000272

Links to Exploration step

PMC:3433088

Curation

No country items

Robert J. Kreitman

<affiliation><nlm:aff wicri:cut=", and" id="aff6">Clinical Immunotherapy Section, Laboratory of Molecular Biology</nlm:aff>
<wicri:noCountry code="subfield">Laboratory of Molecular Biology</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</title>
<author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Morris, John C" sort="Morris, John C" uniqKey="Morris J" first="John C." last="Morris">John C. Morris</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="aff4">Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Division of Hematology-Oncology, University of Cincinnati, Cincinnati</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stewart, Donn M" sort="Stewart, Donn M" uniqKey="Stewart D" first="Donn M." last="Stewart">Donn M. Stewart</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Urquhart, Nicole E" sort="Urquhart, Nicole E" uniqKey="Urquhart N" first="Nicole E." last="Urquhart">Nicole E. Urquhart</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff>
<country xml:lang="fr">Jamaïque</country>
<wicri:regionArea>Department of Pathology, University of the West Indies, Mona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Janik, John E" sort="Janik, John E" uniqKey="Janik J" first="John E." last="Janik">John E. Janik</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kreitman, Robert J" sort="Kreitman, Robert J" uniqKey="Kreitman R" first="Robert J." last="Kreitman">Robert J. Kreitman</name>
<affiliation><nlm:aff wicri:cut=", and" id="aff6">Clinical Immunotherapy Section, Laboratory of Molecular Biology</nlm:aff>
<wicri:noCountry code="subfield">Laboratory of Molecular Biology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lita, Elena" sort="Lita, Elena" uniqKey="Lita E" first="Elena" last="Lita">Elena Lita</name>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Conlon, Kevin" sort="Conlon, Kevin" uniqKey="Conlon K" first="Kevin" last="Conlon">Kevin Conlon</name>
<affiliation wicri:level="2"><nlm:aff id="aff7">Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wharfe, Gilian" sort="Wharfe, Gilian" uniqKey="Wharfe G" first="Gilian" last="Wharfe">Gilian Wharfe</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff>
<country xml:lang="fr">Jamaïque</country>
<wicri:regionArea>Department of Pathology, University of the West Indies, Mona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Waldmann, Thomas A" sort="Waldmann, Thomas A" uniqKey="Waldmann T" first="Thomas A." last="Waldmann">Thomas A. Waldmann</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kaushal, Aradhana" sort="Kaushal, Aradhana" uniqKey="Kaushal A" first="Aradhana" last="Kaushal">Aradhana Kaushal</name>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22730536</idno>
<idno type="pmc">3433088</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433088</idno>
<idno type="RBID">PMC:3433088</idno>
<idno type="doi">10.1182/blood-2012-01-401349</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000272</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000272</idno>
<idno type="wicri:Area/Pmc/Curation">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000271</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</title>
<author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Morris, John C" sort="Morris, John C" uniqKey="Morris J" first="John C." last="Morris">John C. Morris</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="aff4">Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Division of Hematology-Oncology, University of Cincinnati, Cincinnati</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Stewart, Donn M" sort="Stewart, Donn M" uniqKey="Stewart D" first="Donn M." last="Stewart">Donn M. Stewart</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Urquhart, Nicole E" sort="Urquhart, Nicole E" uniqKey="Urquhart N" first="Nicole E." last="Urquhart">Nicole E. Urquhart</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff>
<country xml:lang="fr">Jamaïque</country>
<wicri:regionArea>Department of Pathology, University of the West Indies, Mona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Janik, John E" sort="Janik, John E" uniqKey="Janik J" first="John E." last="Janik">John E. Janik</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kreitman, Robert J" sort="Kreitman, Robert J" uniqKey="Kreitman R" first="Robert J." last="Kreitman">Robert J. Kreitman</name>
<affiliation><nlm:aff wicri:cut=", and" id="aff6">Clinical Immunotherapy Section, Laboratory of Molecular Biology</nlm:aff>
<wicri:noCountry code="subfield">Laboratory of Molecular Biology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lita, Elena" sort="Lita, Elena" uniqKey="Lita E" first="Elena" last="Lita">Elena Lita</name>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Conlon, Kevin" sort="Conlon, Kevin" uniqKey="Conlon K" first="Kevin" last="Conlon">Kevin Conlon</name>
<affiliation wicri:level="2"><nlm:aff id="aff7">Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wharfe, Gilian" sort="Wharfe, Gilian" uniqKey="Wharfe G" first="Gilian" last="Wharfe">Gilian Wharfe</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff>
<country xml:lang="fr">Jamaïque</country>
<wicri:regionArea>Department of Pathology, University of the West Indies, Mona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Waldmann, Thomas A" sort="Waldmann, Thomas A" uniqKey="Waldmann T" first="Thomas A." last="Waldmann">Thomas A. Waldmann</name>
<affiliation wicri:level="2"><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kaushal, Aradhana" sort="Kaushal, Aradhana" uniqKey="Kaushal A" first="Aradhana" last="Kaushal">Aradhana Kaushal</name>
<affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Blood</title>
<idno type="ISSN">0006-4971</idno>
<idno type="eISSN">1528-0020</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; <italic>P</italic>
 = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control across ATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.</p>
</div>
</front>
</TEI>
<pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Blood</journal-id>
<journal-id journal-id-type="iso-abbrev">Blood</journal-id>
<journal-id journal-id-type="hwp">bloodjournal</journal-id>
<journal-id journal-id-type="pmc">blood</journal-id>
<journal-id journal-id-type="publisher-id">Blood</journal-id>
<journal-title-group><journal-title>Blood</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-4971</issn>
<issn pub-type="epub">1528-0020</issn>
<publisher><publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">22730536</article-id>
<article-id pub-id-type="pmc">3433088</article-id>
<article-id pub-id-type="publisher-id">2011/401349</article-id>
<article-id pub-id-type="doi">10.1182/blood-2012-01-401349</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials and Observations</subject>
</subj-group>
<subj-group subj-group-type="leader"><subject>Brief Report</subject>
</subj-group>
<subj-group subj-group-type="heading"><subject>Lymphoid Neoplasia</subject>
</subj-group>
</article-categories>
<title-group><article-title>Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Simone</surname>
<given-names>Charles B.</given-names>
<suffix>II</suffix>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Morris</surname>
<given-names>John C.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Stewart</surname>
<given-names>Donn M.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Urquhart</surname>
<given-names>Nicole E.</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Janik</surname>
<given-names>John E.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kreitman</surname>
<given-names>Robert J.</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lita</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Conlon</surname>
<given-names>Kevin</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wharfe</surname>
<given-names>Gilian</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Waldmann</surname>
<given-names>Thomas A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Kaushal</surname>
<given-names>Aradhana</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label>
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</aff>
<aff id="aff2"><label>2</label>
Radiation Oncology Branch and</aff>
<aff id="aff3"><label>3</label>
Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</aff>
<aff id="aff4"><label>4</label>
Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</aff>
<aff id="aff5"><label>5</label>
Department of Pathology, University of the West Indies, Mona, Jamaica; and</aff>
<aff id="aff6"><label>6</label>
Clinical Immunotherapy Section, Laboratory of Molecular Biology, and</aff>
<aff id="aff7"><label>7</label>
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</aff>
</contrib-group>
<pub-date pub-type="ppub"><day>30</day>
<month>8</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epreprint"><day>22</day>
<month>6</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>30</day>
<month>8</month>
<year>2013</year>
</pub-date>
<pmc-comment> PMC Release delay is 12 months and 0 days and was based on the 
 					. </pmc-comment>
      <volume>120</volume>
<issue>9</issue>
<fpage>1816</fpage>
<lpage>1819</lpage>
<history><date date-type="received"><day>7</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted"><day>6</day>
<month>6</month>
<year>2012</year>
</date>
</history>
<permissions><copyright-statement>© 2012 by The American Society of Hematology</copyright-statement>
<copyright-year>2012</copyright-year>
</permissions>
<self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zh803512001816.pdf"></self-uri>
<abstract><p>Human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; <italic>P</italic>
 = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control across ATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.</p>
</abstract>
<funding-group><award-group><funding-source id="CS100">National Institutes of Health</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Pmc/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000271 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000271 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    CobaltMaghrebV1
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:3433088
   |texte=   Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:22730536" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CobaltMaghrebV1

This area was generated with Dilib version V0.6.32.
Data generation: Tue Nov 14 12:56:51 2017. Site generation: Mon Feb 12 07:59:49 2024

	Serveur d'exploration sur le cobalt au Maghreb
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le cobalt au Maghreb

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki